OCS
$26.92
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally.
Recent News
Oculis Holding (NasdaqGM:OCS) Valuation Check After Strong Three Year Gains And Recent Share Price Pullback
What Oculis Holding’s Recent Performance Tells You Oculis Holding (NasdaqGM:OCS) has drawn investor attention after a strong past 3 months return of about 31%, alongside a year to date gain of roughly 35% and a 1 year total return near 43%. See our latest analysis for Oculis Holding. In the short term, the 1 week share price return of about an 8% decline and the 1 month share price return of roughly a 5% decline contrast with a 3 month share price return near 31% and a 3 year total...
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) delivered earnings and revenue surprises of -17.70% and +83.68%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Oculis Holding (NasdaqGM:OCS) Valuation Check As Privosegtor Wins FDA Breakthrough Therapy Status
Oculis Holding (OCS) is back in focus after the U.S. FDA granted breakthrough therapy designation to its neuroprotective candidate Privosegtor for optic neuritis, supported by positive Phase 2 ACUITY trial data. See our latest analysis for Oculis Holding. The breakthrough therapy designation appears to have coincided with stronger trading interest, with a 1 day share price return of 4.72% and 7 day share price return of 15.35% at a latest share price of $23.07. Over longer periods, the stock...
Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis
Oculis Holding AG recently reported that its neuroprotective candidate Privosegtor received U.S. FDA Breakthrough Therapy designation for optic neuritis, supported by positive Phase 2 ACUITY data and the launch of the PIONEER registrational program in optic neuropathies. The company is also advancing OCS-01 eye drops toward potential U.S. approval in diabetic macular edema, targeting multi-billion-dollar markets with non-invasive and first-in-class treatment approaches. We’ll now examine how...
J.P. Morgan Bangs the Drum on These 2 ‘Strong Buy’ Stocks
We’ve turned the calendar on 2026, and the market’s focus is on what comes next. The big questions haven’t changed: can the bull run extend into the new year? Is AI showing signs of a bubble, or is it still in the early innings? And will the Fed continue cutting rates? The answers to these will shape market direction in the months ahead and well into the year. Ken Goldman of the JPMorgan’s Americas Equity Research team argues that resilient fundamentals and easing financial conditions support fu